Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropept...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (196 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545526504498
ctrlnum (CKB)5400000000041063
(oapen)https://directory.doabooks.org/handle/20.500.12854/69163
(EXLCZ)995400000000041063
collection bib_alma
record_format marc
spelling Kuo, Hann-Chorng edt
Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
1 electronic resource (196 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.
English
Medicine bicssc
urethra
onabotulinumtoxinA
voiding
therapeutic outcome
lower urinary tract symptoms
botulinum toxin
benign prostatic hyperplasia
prostatitis
inflammation
Botulinum toxin
chronic prostatitis
interstitial cystitis
treatment
bladder pain
botulinum toxin A
predictor
maximal bladder capacity
hydrodistention
urethral sphincter
urethral sphincter dysfunction
urodynamics
drug delivery
overactive bladder
painful bladder syndrome
molecular mechanism
chronic pelvic pain syndrome
pelvic pain
functional urology disorder
human
network meta-analysis
OnabotulinumtoxinA
peripheral tibial nerve stimulation
sacral neuromodulation
bladder
sensation
therapy
pathophysiology
diabetes mellitus
mid-urethral sling
antimuscarinics
urinary incontinence
functional urological disorders
pain
neurogenic detrusor overactivity
3-03936-670-X
3-03936-671-8
Kuo, Hann-Chorng oth
language English
format eBook
author2 Kuo, Hann-Chorng
author_facet Kuo, Hann-Chorng
author2_variant h c k hck
author2_role Sonstige
title Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
spellingShingle Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_full Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_fullStr Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_full_unstemmed Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_auth Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_new Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
title_sort botulinum toxin treatment for pain and inflammation in functional urological disorders
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2020
physical 1 electronic resource (196 p.)
isbn 3-03936-670-X
3-03936-671-8
illustrated Not Illustrated
work_keys_str_mv AT kuohannchorng botulinumtoxintreatmentforpainandinflammationinfunctionalurologicaldisorders
status_str n
ids_txt_mv (CKB)5400000000041063
(oapen)https://directory.doabooks.org/handle/20.500.12854/69163
(EXLCZ)995400000000041063
carrierType_str_mv cr
is_hierarchy_title Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders
author2_original_writing_str_mv noLinkedField
_version_ 1796651990276636672
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03748nam-a2200817z--4500</leader><controlfield tag="001">993545526504498</controlfield><controlfield tag="005">20231214132944.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69163</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041063</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kuo, Hann-Chorng</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (196 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethra</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">onabotulinumtoxinA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">voiding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lower urinary tract symptoms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">botulinum toxin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">benign prostatic hyperplasia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Botulinum toxin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic prostatitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interstitial cystitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">botulinum toxin A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">maximal bladder capacity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hydrodistention</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethral sphincter</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urethral sphincter dysfunction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urodynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">overactive bladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">painful bladder syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular mechanism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic pelvic pain syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pelvic pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional urology disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OnabotulinumtoxinA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peripheral tibial nerve stimulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sacral neuromodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sensation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathophysiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diabetes mellitus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mid-urethral sling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimuscarinics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">urinary incontinence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">functional urological disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurogenic detrusor overactivity</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-670-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-671-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuo, Hann-Chorng</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:37:52 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338010500004498&amp;Force_direct=true</subfield><subfield code="Z">5338010500004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338010500004498</subfield></datafield></record></collection>